Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the Ovarian Tumour Domain Protein, Fam105a, in Fibrostenotic Inflammatory Bowel Disease
FY 2021-22
Summary
Inflammatory bowel disease (IBD) is a chronic, debilitating condition which affects thousands of Canadians yearly and for which there are few long-termed therapies. This holds especially true for patients afflicted with fibrostenotic IBD, such as ulcerative colitis (UC) and Crohn's disease (CD), who often suffer from intestinal strictures due to fibrosis. The development of fibrosis and intestinal strictures found in fibrostenotic IBD, and in turn, the mechanisms underlying potential fibrosis reversal is poorly understood and so far has been largely, inadequately modeled in mouse models. Recently, our lab discovered that mice lacking the protein Fam105a (Fam105a-/- ) recapitulated human IBD phenotypes. Moreover, in collaboration with Dr. Aleixo Muise, we have identified familial pediatric IBD patients carrying FAM105A variants. Excitingly, both homozygous and heterozygous Fam105a mice exhibited intestinal fibrosis and strictures - a phenotype that has been rarely reported in mouse IBD models to date. This unique mouse IBD model provides us with a novel opportunity to conduct translational therapeutic research in fibrostenotic IBD. We will extensively analyze primary causal fibrotic events and cell types that drive Fam105a dependent intestinal fibrosis. This will be conducted through the visualization of immunofluorescence markers targeting cell proliferation, cell death and subcellular intestinal populations that have been previously shown to be dysregulated in human IBD and CD patient and mice samples. Ultimately, this characterization will help us design an approach to test whether Fam105a reactivation or the knockout of Fam105a targeted cell types can halt or reverse fibrosis.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467186
Name
Thomas Anjali L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Ovarian Tumour Domain Protein, Fam105a, in Fibrostenotic Inflammatory Bowel Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crohn'S Disease; Fam105a; Inflammatory Bowel Disease; Inflammatory Bowel Disease Mouse Model; Mitochondrial Associated Membrane
Abstract
Inflammatory bowel disease (IBD) is a chronic, debilitating condition which affects thousands of Canadians yearly and for which there are few long-termed therapies. This holds especially true for patients afflicted with fibrostenotic IBD, such as ulcerative colitis (UC) and Crohn's disease (CD), who often suffer from intestinal strictures due to fibrosis. The development of fibrosis and intestinal strictures found in fibrostenotic IBD, and in turn, the mechanisms underlying potential fibrosis reversal is poorly understood and so far has been largely, inadequately modeled in mouse models. Recently, our lab discovered that mice lacking the protein Fam105a (Fam105a-/- ) recapitulated human IBD phenotypes. Moreover, in collaboration with Dr. Aleixo Muise, we have identified familial pediatric IBD patients carrying FAM105A variants. Excitingly, both homozygous and heterozygous Fam105a mice exhibited intestinal fibrosis and strictures - a phenotype that has been rarely reported in mouse IBD models to date. This unique mouse IBD model provides us with a novel opportunity to conduct translational therapeutic research in fibrostenotic IBD. We will extensively analyze primary causal fibrotic events and cell types that drive Fam105a dependent intestinal fibrosis. This will be conducted through the visualization of immunofluorescence markers targeting cell proliferation, cell death and subcellular intestinal populations that have been previously shown to be dysregulated in human IBD and CD patient and mice samples. Ultimately, this characterization will help us design an approach to test whether Fam105a reactivation or the knockout of Fam105a targeted cell types can halt or reverse fibrosis.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thomas, Anjali L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~